0001628280-26-030124
SEC filingPrecision BioSciences reported Q1 FY2026 revenue of $10.8M, a significant increase from the prior year, while operating loss narrowed 59% to -$9.1M. The improved performance reflects strategic prioritization of clinical programs and reduced operating costs.
The company reported revenue of $10.8M for Q1 FY2026, a substantial increase from $29.0K in the same period last year. As a clinical-stage gene editing company, Precision BioSciences has not yet generated revenue from product sales, and revenue fluctuations are tied to collaboration and partnership activities. The company continues to expect significant expenses and operating losses for the foreseeable future as it advances the development of its product candidates.
Net cash used in operating activities improved to -$11.9M, compared to -$19.1M in the prior year period. This improvement was driven by a decrease in net loss and an increase in non-cash adjustments, partially offset by changes in operating assets and liabilities. Management has indicated that the company will continue to have funding requirements related to research and development efforts, potential regulatory submissions, and clinical trials. The company may seek additional capital if market conditions are favorable or for strategic considerations.